RT Journal Article
SR Electronic
T1 The Combination of Epirubicin plus Docetaxel as Neoadjuvant Chemotherapy in Locally-advanced Breast Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 581
OP 584
VO 26
IS 1B
A1 HIRANO, AKIRA
A1 SHIMIZU, TADAO
A1 IMAMURA, HIROSHI
A1 WATANABE, OSAMU
A1 KINOSHITA, JUN
A1 OKABE, TOSHIHIRO
A1 KIMURA, KIYOMI
A1 KAMIMURA, MARI
A1 DOMOTO, KAORU
A1 AIBA, MOTOHIKO
A1 OGAWA, KENJI
YR 2006
UL http://ar.iiarjournals.org/content/26/1B/581.abstract
AB Background: The purpose of this study was to evaluate the activity and toxicity of epirubicin plus docetaxel as neoadjuvant chemotherapy for locally advanced breast cancer. Patients and Methods: In this single-center, phase II trial, twenty-one patients with locally advanced breast cancer (T>3 cm or N>1) received epirubicin (70 mg/m2) and docetaxel (60 mg/m2) on Day 1 of each cycle for up to 6 cycles. Results: Clinically complete responses (CR) were observed in 5 patients and partial responses were observed in 14 patients. The clinical response rate was 90.5% (95% confidence interval, 78.0-99.9). Eleven patients (52.4%) underwent breast conserving surgery. Pathological response evaluation revealed 2 CR (9.5%). Grade 4 neutropenia was recorded in 81.0% of the patients and febrile neutropenia occurred in 1 patient. Conclusion: The combination of epirubicin plus docetaxel was an active and well-tolerated treatment for locally-advanced breast cancer. Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved